These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 19098563)

  • 1. Lower facial contouring with botulinum toxin type A.
    Tartaro G; Rauso R; Santagata M; Santillo V; Itro A
    J Craniofac Surg; 2008 Nov; 19(6):1613-7. PubMed ID: 19098563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The medical management of masseteric hypertrophy with botulinum toxin.
    Finn S; Ryan P; Sleeman D
    J Ir Dent Assoc; 2000; 46(3):84-6. PubMed ID: 11323940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The treatment of masseter hypertrophy with botulinum toxin type A.
    Al-Ahmad HT; Al-Qudah MA
    Saudi Med J; 2006 Mar; 27(3):397-400. PubMed ID: 16532107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of botulinum toxin type A injection on lower facial contouring evaluated using a three-dimensional laser scan.
    Shim WH; Yoon SH; Park JH; Choi YC; Kim ST
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2161-6. PubMed ID: 21134047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of botulinum toxin type A injection into human masseter muscle on stimulated parotid saliva flow rate.
    Kwon JS; Kim ST; Jeon YM; Choi JH
    Int J Oral Maxillofac Surg; 2009 Apr; 38(4):316-20. PubMed ID: 19231136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic satisfaction and dissatisfaction in patients with spinal cord lesions and detrusor sphincter dyssynergia who received detrusor botulinum toxin a injection.
    Kuo HC
    Urology; 2008 Nov; 72(5):1056-60. PubMed ID: 18533231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Botulinum toxin type A treatment of cosmetically disturbing masseteric hypertrophy].
    Rijsdijk BA; van ES RJ; Zonneveld FW; Steenks MH; Koole R
    Ned Tijdschr Geneeskd; 1998 Mar; 142(10):529-32. PubMed ID: 9623101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of botulinum toxin for the treatment of temporomandibular disorder.
    Freund B; Schwartz M
    Oral Health; 1998 Feb; 88(2):32-7. PubMed ID: 9610334
    [No Abstract]   [Full Text] [Related]  

  • 9. Botulinum toxin as an alternative for the treatment of aesthetic deformities.
    Barbosa MV; Nahas FX; Ferreira LM; Al-Ahmad HT; Al-Qudah M
    Saudi Med J; 2006 Oct; 27(10):1613; author reply 1613. PubMed ID: 17013500
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects on craniofacial growth and development of unilateral botulinum neurotoxin injection into the masseter muscle.
    Tsai CY; Chiu WC; Liao YH; Tsai CM
    Am J Orthod Dentofacial Orthop; 2009 Feb; 135(2):142.e1-6; discussion 142-3. PubMed ID: 19201315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botox facial slimming/facial sculpting: the role of botulinum toxin-A in the treatment of hypertrophic masseteric muscle and parotid enlargement to narrow the lower facial width.
    Wu WT
    Facial Plast Surg Clin North Am; 2010 Feb; 18(1):133-40. PubMed ID: 20206096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Commentary: The effect of botulinum toxin type A injection on lower facial contouring evaluated using a three-dimensional laser scan.
    Ahn KY
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2167. PubMed ID: 21244566
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of unilateral masseter hypertrophy with botulinum toxin in two cases.
    Işeri M; Işeri PK
    Kulak Burun Bogaz Ihtis Derg; 2004; 12(3-4):99-102. PubMed ID: 16010109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intramuscular nerve distribution of the masseter muscle as a basis for botulinum toxin injection.
    Kim DH; Hong HS; Won SY; Kim HJ; Hu KS; Choi JH; Kim HJ
    J Craniofac Surg; 2010 Mar; 21(2):588-91. PubMed ID: 20489458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin A injection under electromyographic guidance for treatment of spasmodic dysphonia.
    Casserly P; Timon C
    J Laryngol Otol; 2008 Jan; 122(1):52-6. PubMed ID: 17470307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Commentary.
    De Almeida AR
    Dermatol Surg; 2009 Dec; 35(12):1907. PubMed ID: 20050146
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia.
    Factor SA; Molho ES; Evans S; Feustel PJ
    Mov Disord; 2005 Sep; 20(9):1152-60. PubMed ID: 15954134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Satisfaction with urethral injection of botulinum toxin A for detrusor sphincter dyssynergia in patients with spinal cord lesion.
    Kuo HC
    Neurourol Urodyn; 2008; 27(8):793-6. PubMed ID: 18508331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin type A for the treatment of sialorrhoea in amyotrophic lateral sclerosis: a clinical and neurophysiological study.
    Gilio F; Iacovelli E; Frasca V; Gabriele M; Giacomelli E; Picchiori F; Soldo P; Cipriani AM; Ruoppolo G; Inghilleri M
    Amyotroph Lateral Scler; 2010 Aug; 11(4):359-63. PubMed ID: 19929745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxin in the treatment of dystonias--a hospital based study.
    Gupta M; Singh G; Khwaja G
    J Assoc Physicians India; 2003 May; 51():447-53. PubMed ID: 12974424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.